Assessing pharmacological interventions for bone metastases

the need for more patient-centered outcomes

John A Ford, Graham Mowatt, Rob Jones

Research output: Contribution to journalArticle

5 Citations (Scopus)
4 Downloads (Pure)

Abstract

Bone metastases are associated with a broad spectrum of clinical sequelae. Pain, reduced mobility, skeletal complications and treatment-related events reduce quality of life. Numerous randomized controlled trials have evaluated pharmacological interventions to treat bone metastases. The primary outcomes used have evolved over the past 25 years; from improvement in pain to time to first skeletal-related event (SRE). In the current definition, a SRE consists of pathological fracture, spinal cord compression or the need for radiotherapy or surgery to the bone. Currently used outcomes can detect small differences between interventions. However, there are several limitations to SRE-related outcomes. In this article we illustrate the evolution of outcomes used in randomized controlled trials, critically appraising current outcomes used and proposing that more patient-centered outcomes are needed.
Original languageEnglish
Pages (from-to)271-279
Number of pages9
JournalExpert Review of Clinical Pharmacology
Volume5
Issue number3
DOIs
Publication statusPublished - May 2012

Fingerprint

Pharmacology
Neoplasm Metastasis
Bone and Bones
Randomized Controlled Trials
Pain
Spontaneous Fractures
Spinal Cord Compression
Radiotherapy
Quality of Life
Therapeutics

Cite this

Assessing pharmacological interventions for bone metastases : the need for more patient-centered outcomes. / Ford, John A; Mowatt, Graham; Jones, Rob.

In: Expert Review of Clinical Pharmacology, Vol. 5, No. 3, 05.2012, p. 271-279.

Research output: Contribution to journalArticle

@article{e1b1218f3b1b47b4a49789634371946b,
title = "Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes",
abstract = "Bone metastases are associated with a broad spectrum of clinical sequelae. Pain, reduced mobility, skeletal complications and treatment-related events reduce quality of life. Numerous randomized controlled trials have evaluated pharmacological interventions to treat bone metastases. The primary outcomes used have evolved over the past 25 years; from improvement in pain to time to first skeletal-related event (SRE). In the current definition, a SRE consists of pathological fracture, spinal cord compression or the need for radiotherapy or surgery to the bone. Currently used outcomes can detect small differences between interventions. However, there are several limitations to SRE-related outcomes. In this article we illustrate the evolution of outcomes used in randomized controlled trials, critically appraising current outcomes used and proposing that more patient-centered outcomes are needed.",
author = "Ford, {John A} and Graham Mowatt and Rob Jones",
note = "PMID: 22697590 [PubMed - indexed for MEDLINE]",
year = "2012",
month = "5",
doi = "10.1586/ecp.12.21",
language = "English",
volume = "5",
pages = "271--279",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Assessing pharmacological interventions for bone metastases

T2 - the need for more patient-centered outcomes

AU - Ford, John A

AU - Mowatt, Graham

AU - Jones, Rob

N1 - PMID: 22697590 [PubMed - indexed for MEDLINE]

PY - 2012/5

Y1 - 2012/5

N2 - Bone metastases are associated with a broad spectrum of clinical sequelae. Pain, reduced mobility, skeletal complications and treatment-related events reduce quality of life. Numerous randomized controlled trials have evaluated pharmacological interventions to treat bone metastases. The primary outcomes used have evolved over the past 25 years; from improvement in pain to time to first skeletal-related event (SRE). In the current definition, a SRE consists of pathological fracture, spinal cord compression or the need for radiotherapy or surgery to the bone. Currently used outcomes can detect small differences between interventions. However, there are several limitations to SRE-related outcomes. In this article we illustrate the evolution of outcomes used in randomized controlled trials, critically appraising current outcomes used and proposing that more patient-centered outcomes are needed.

AB - Bone metastases are associated with a broad spectrum of clinical sequelae. Pain, reduced mobility, skeletal complications and treatment-related events reduce quality of life. Numerous randomized controlled trials have evaluated pharmacological interventions to treat bone metastases. The primary outcomes used have evolved over the past 25 years; from improvement in pain to time to first skeletal-related event (SRE). In the current definition, a SRE consists of pathological fracture, spinal cord compression or the need for radiotherapy or surgery to the bone. Currently used outcomes can detect small differences between interventions. However, there are several limitations to SRE-related outcomes. In this article we illustrate the evolution of outcomes used in randomized controlled trials, critically appraising current outcomes used and proposing that more patient-centered outcomes are needed.

U2 - 10.1586/ecp.12.21

DO - 10.1586/ecp.12.21

M3 - Article

VL - 5

SP - 271

EP - 279

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -